
AgeX Therapeutics AGE
Quarterly report 2025-Q3
added 11-13-2025
AgeX Therapeutics P/S Ratio 2011-2025 | AGE
Annual P/S Ratio AgeX Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.099 | 0.02 | 211 | 35.1 | 30.4 | 98.3 | - | 79.2 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 211 | 0.02 | 64.9 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbCellera Biologics
ABCL
|
29.8 | $ 3.56 | -2.51 % | $ 1.05 B | ||
|
AC Immune SA
ACIU
|
35 | $ 2.82 | -2.07 % | $ 229 M | ||
|
ADiTx Therapeutics
ADTX
|
0.442 | $ 3.05 | 4.81 % | $ 40.2 K | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
Abeona Therapeutics
ABEO
|
42.7 | $ 4.81 | -1.23 % | $ 103 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Amneal Pharmaceuticals
AMRX
|
0.654 | $ 11.96 | 0.13 % | $ 3.7 B | ||
|
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | ||
|
argenx SE
ARGX
|
311 | $ 901.39 | -1.59 % | $ 25 B | ||
|
Armata Pharmaceuticals
ARMP
|
110 | $ 5.88 | 1.03 % | $ 212 M | ||
|
Achieve Life Sciences
ACHV
|
3.19 | $ 4.69 | -1.88 % | $ 93 M | ||
|
BioDelivery Sciences International
BDSI
|
1.85 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Ascendis Pharma A/S
ASND
|
947 | $ 206.12 | -1.18 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
131 | $ 3.36 | -1.95 % | $ 8.08 B | ||
|
Autolus Therapeutics plc
AUTL
|
1.37 K | $ 1.54 | -1.92 % | $ 393 M | ||
|
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
34 | - | -15.15 % | $ 60.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Baudax Bio
BXRX
|
0.614 | - | 0.59 % | $ 63 K | ||
|
AbbVie
ABBV
|
22.7 | $ 226.39 | -1.0 % | $ 400 B | ||
|
Cara Therapeutics
CARA
|
2.58 | - | -3.03 % | $ 260 M | ||
|
CymaBay Therapeutics
CBAY
|
110 | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | ||
|
Codiak BioSciences
CDAK
|
10.5 | - | -55.98 % | $ 2.15 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
6.58 | $ 15.13 | -13.34 % | $ 2.23 B | ||
|
Avid Bioservices
CDMO
|
3.03 | - | - | $ 789 M | ||
|
Biogen
BIIB
|
2 | $ 182.61 | 0.35 % | $ 26.6 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Beam Therapeutics
BEAM
|
39.4 | $ 27.45 | -5.05 % | $ 2.26 B | ||
|
BioMarin Pharmaceutical
BMRN
|
4.6 | $ 53.01 | -1.51 % | $ 10.1 B | ||
|
BioNTech SE
BNTX
|
35.7 | $ 96.12 | 0.13 % | $ 27.2 B | ||
|
Clearside Biomedical
CLSD
|
12.3 | - | - | $ 25.3 M | ||
|
Celsion Corporation
CLSN
|
26.1 | - | -6.63 % | $ 13.9 M | ||
|
Clovis Oncology
CLVS
|
1.55 | - | -7.23 % | $ 13 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Chimerix
CMRX
|
320 | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
41.3 | - | - | $ 401 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
18.6 | $ 9.44 | -1.82 % | $ 611 M |